severe adverse reaction to vemurafenib in a pregnant woman with metastatic melanoma

Clicks: 123
ID: 208130
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.
Reference Key
de haan2018casesevere Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Jorine de Haan;Johannes V. van Thienen;Michael Casaer;Rebekka A. Hannivoort;Kristel Van Calsteren;Minke van Tuyl;Mathilde M. van Gerwen;Anne Debeer;Frédéric Amant;Rebecca C. Painter
Journal multi-span large bridges - proceedings of the international conference on multi-span large bridges, 2015
Year 2018
DOI
10.1159/000487128
URL
https://www.karger.com/Article/FullText/487128
Keywords
pregnancy vemurafenib Oncology including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.